India's pharmaceutical manufacturing sector has emerged as a critical backbone of the United States healthcare system, complicating President Donald Trump's push to reshore generic drug production, according to a report by The Star. The findings underscore the structural depth of India's role in global medicine supply chains — and the steep economic cost of dismantling it.

Scale of India's Pharma Footprint

A manufacturing facility operated by a leading pharmaceuticals firm in Hyderabad illustrates the industry's scale: nearly 1,900 workers produce more than 100 generic medicines at the plant, ranging from cholesterol and allergy treatments to antidepressants. The facility churns out close to one billion oral doses every month, with roughly three-quarters of that output destined for the US market.

At the national level, generic medicines account for approximately 90 per cent of all prescriptions dispensed in the United States, and Indian manufacturers supply around 40 per cent of those medicines. That dependency has made India effectively indispensable to American healthcare affordability.

Trump's Tariff Threat and Its Limits

The Trump administration has proposed steep tariffs on imported generic drugs as part of a broader domestic manufacturing push — including a 100 per cent levy from 2028, rising to a 200 per cent tariff a year later. The intent is to incentivise US-based production of pharmaceuticals.

However, industry executives and healthcare experts argue that decades of accumulated cost advantages make large-scale reshoring deeply challenging, according to the report. Producing most generic medicines in the United States could cost four times more than manufacturing them in India, according to industry estimates. Lower labour costs, faster factory construction timelines, and extensive technical expertise continue to give Indian drugmakers a structural competitive edge that tariffs alone are unlikely to neutralise.

India's Pharmaceutical Rise: A Five-Decade Story

The industry's foundations were laid in the 1970s, when India prioritised affordable access to medicines and built strong capabilities in reverse-engineering and large-scale pharmaceutical manufacturing. What began as a domestic policy imperative gradually evolved into a global supply powerhouse.

Concerns over manufacturing quality once clouded the sector's reputation, but leading drugmakers say regulatory oversight has since strengthened significantly. Major producers now face frequent inspections by global regulators and have made heavy investments in compliance infrastructure.

The Case for Deeper US-India Cooperation

Industry leaders are pushing back on the decoupling narrative, arguing instead for deeper collaboration between the two countries — particularly as both seek to reduce their dependence on China for active pharmaceutical ingredients (APIs) and strengthen overall supply-chain resilience, according to the report.

This comes amid broader geopolitical shifts that have prompted both Washington and New Delhi to reassess their pharmaceutical supply chains. Notably, any sharp disruption to Indian generic supplies could ripple directly into US drug prices and healthcare access, given the volume and affordability profile of the medicines involved.

As the debate over tariffs and reshoring intensifies, the economic arithmetic — and the public health stakes — suggest that the US-India pharmaceutical relationship is likely to remain a central tension in bilateral trade discussions in the years ahead.